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(Chairman K.E. Halnan)
Differentiation of human teratocarcinoma stem cells:
Analysis with monoclonal antibodies
P.N. Goodfellow1, G. Banting1' 2 & P.W. Andrews
1Human Molecular Genetics Laboratory, Imperial
Cancer Research Fund, London, UK and 2Wistar
Institute, Philadelphia, USA
McAbs are ideal tools for analysing complex
mixtures of cells and cell lineages. Embryonal
carcinoma cells (ECC) are the pluri-potent stem
cells of mouse teratocarcinomas. As well as in vivo
differentiation these cells can also be induced to
differentiate in vitro. This differentiation has been
studied by McAbs which are specific either for the
stem cell population or the differentiated
derivatives. In comparison with the mouse system
little is known about the biology of human
teratocarcinomas. We have isolated human ECC
from testicular teratocarcinomas by passage
through nude mice. The stem cells have been
defined by the ability to differentiate in vitro and in
vivo and reactivity with several different McAbs.
Using these reagents we have defined conditions
which result in the production of neurons in
culture.
ANTIGEN-ANTIBODY INTERACTIONS
(Chairman W.F. Bodmer)
The heterogeneity of human breast carcinomas
A. Munro Neville
Ludwig Institute for Cancer Research (London
Branch), Royal Marsden Hospital, Sutton, Surrey
SM2 5PX, UK
Morphological and functional heterogeneity of
human and experimental neoplasms has long been
recognised. Examples include drug resistance, the
ability to metastasise, receptor status, and hormone
production, etc. The recent availability of a wide
range of McAbs directed against the cell surface, of
both normal and neoplastic cells, has shown
another form of heterogeneity. Cells of a similar
morphological type may or may not express a
variety of different epitopes detected by these
McAbs. In the main, such McAbs tend to be
directed against carbohydrate epitopes present on
cell surface glycoproteins and/or glycolipids. The
rationale behind this heterogeneity is poorly
understood.
Other McAbs directed against cytoplasmic
constituents, such as the steroid receptors or
keratins, both of which are protein in nature, also
reveal functional heterogeneity.
Nonetheless, antibodies can be derived which will
detect a majority of or nearly all normal and
neoplastic cells in a particular tissue. Such
antibodies may have utility with respect to the
detection ofmetastatic disease and its therapy.
The organisers are very grateful to the Imperial Cancer
Research Fund for their support.
Course Organisers: A.A. Epenetos & K.E. Halnan,
Royal Postgraduate Medical School & Hammersmith
Hospital, London W12 OHS.
Course Secretary: A. Freemantle, Department of
Medical Physics, Royal Postgraduate Medical School &
Hammersmith Hospital, London W12 OHS, UK.
Tumour markers
K.D. Bagshawe
Department of Medical Oncology, Charing Cross
Hospital Medical School, London, W6 8RF, UK
Tumour markers found a place in the management550 ABSTRACTS OF ORAL PRESENTATIONS
of some cancers in the pre-monoclonal era and the
principles of their application were established.
Three main areas of application have been defined
and if markers comparable to those used in the
management of choriocarcinoma and germ cell
tumours were identified for other tumours it would
be a major advance. The identification of markers
by pre-monoclonal technology was tedious and
usually unfruitful; with monoclonal technology
many problems remain but a trickle of new and
useful antigens seems to have begun. Preliminary
evidence indicates that the new markers show a
wide expression amongst carcinomas rather like
that of CEA.
McAbs directed at secreted antigens do present
some problems in immunoassay but much present
interest is focussed on their use as agents for
targeting. The characteristics of the antigenic
targets, whether secreted, shed or membrane bound
may not be important in diagnostic targeting but
are central to selecting the means of antibody-based
therapeutic attack.
Investigation of the structure and function of human
epidermal growth factor receptor using McAbs and
polyclonal antisera raised to synthetic amino acid
sequences
W.J. Gullick & M.D. Waterfield
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, WC2A 3PX, UK
The epidermal growth factor receptor (EGFR) is a
transmembrane glycoprotein found on epidermal
and other cell types. The binding of EGF, a small
polypeptide hormone, to its receptor may stimulate
mitogenesis in target cells. Several effects upon cell
morphology and biochemical activities have been
described. EGF also stimulates its receptor to
autophosphorylate and to phosphorylate cellular
proteins on tyrosine.
We have prepared several McAbs to the EGFR
which have been used to develop a
radioimmunDassay for EGFR in solution which
allowed immunoaffinity purification of substantial
quantities of protein. Direct sequencing of this lead
to the discovery that the EGFR is highly related to
the transforming gene product termed v-erb-B
present in several isolates of avian erythroblastosis
virus. Molecular cloning of the human EGFR
coding sequences has allowed the prediction of its
primary structure. We have synthesised twelve
selected peptides from v-erb-B and the EGFR and
have generated antisera against them in rabbits.
These reagents provide the first probes for the
cytoplasmic domain of the receptor and are being
used to test the current model of its transmembrane
orientation. We are also examining EGFR structure
and function in normal and transformed cell lines
and in normal tissues and primary tumours.
Blood group antigens on tumours
E.S. Lennox, P.J. Finan' & P. Vowden2
MRC Laboratory of Molecular Biology, Cambridge,
'Department of Surgery, St James' University
Hospital, Leeds, and 2Seacroft Hospital, Leeds, UK.
It is easy to imagine that altered carbohydrate
metabolism might be a source of antigen differences
between neoplastic cells and their normal
counterpart. In fact this has turned up in two
circumstances:
1. Incomplete ABO antigens, i.e. Lewis substances
have been identified on several types of tumours.
2. Loss or gain of ABO antigens has been reported.
We re-examined, using monoclonal anti A and
anti B reagents, the ABO status of several kinds of
tumours:
1. Transitional epithelial cell carcinomas of the
bladder - 8/39 of these lacked expected blood
group isoantigen and this loss correlated with
incidence of invasive recurrence (Finan et al.
(1982), Br. J. Urol. 54, 720).
2. Gastric carcinoma - complete loss of isoantigen
expression in 6/17 cases (Finan et al. (1983), J.
Natl Cancer Inst. 80, 679).
3. Carcinoma of colon (left side) - normally
negative, these occasionally acquire isoantigen
(Vowden et al., unpublished).
Normal and neoplastic leucocytes examined by
McAbs
D. Catovsky
MRC Leukaemia Unit, Royal Postgraduate Medical
School, London, W12 OHS, UK
The development of McAbs has provided a unique
opportunity for the study of the antigenic make-up
of normal leucocytes and, by extension, for a more
objective characterisation of neoplastic cells. An
increasing range of McAbs is now available for
these purposes; some of them are specific for B or
T lymphoid cells and others react with antigens
unique to myeloid cells. A few McAb were thought
initially to be "specific' for neoplastic cells, i.e.
hairy cells (HC2), Sezary cells (BE2), ReedABSTRACTS OF ORAL PRESENTATIONS 551
Sternberg cells (Ki-l) but have now been
demonstrated in normal cells which are presumably
the normal counterparts of the malignant cells. By
means of a small battery of reagents it is now
possible to define the membrane phenotype of acute
leukaemias and NH lymphomas which result from
the proliferation of B or T cells at different stages
of maturation. Several McAb are now essential for
the classification of acute and chronic leukaemias.
For example J5, B4 and anti HLA-Dr are positive
in common-ALL, 3A1, Tl1, T17 and often T6 are
positive in T-ALL and T-lymphoblastic lymphoma.
Hairy cell leukaemia has unique membrane
features, positive with HC2, FMC7, HLA-Dr and
anti-TAC, which are identical to those of activated
B-cells. Most types of T-cell leukaemia can be
distinguished with McAbs reactive with mature T-
cell antigens: T3, T4, T8, Leu7, Leul5, etc.
Difficulties in classifying poorly differentiated blasts
can now be overcome with McAbs that are specific
for platelet glycoproteins (present in
megakaryoblasts), glycophorin A (in erythroid
precursors), and early antigens of granulocyte and
monocytes (MY9, OKM1, etc.).
Improved detection of colon carcinoma by using
tomoscintigraphy and 1-123 labelled F(ab')2
fragments of anti-CEA McAbs
J.-P. Mach, F. Buchegger, J.Ph. Grob, V. von
Fliedner, A. Bischof-Delaloye & B. Delaloye
Ludwig Institute and Division of Nuclear Medicine,
Lausanne, Switzerland
After having shown that a first McAb against CEA
gave encouraging results for detection of colon
carcinoma in patients by external photoscanning
and tomoscintigraphy (Mach et al. (1981) Immunol.
Today, 2, 239; Berche et al. (1982), Br. Med. J.,
285, 1477), we screened a series of 26 new anti-
CEA McAb, first in vitro for high affinity towards
CEA and no cross-reactivity with normal
granulocytes (Haskell et al. (1983), Cancer Res. 43,
3857). Four McAbs with high affinity for CEA
(ranging from 5.8 x 108 to 1.8 x 1010), their F(ab')2
and Fab fragments were then tested for in vivo
localisation in human carcinoma grafted in nude
mice. One of the best McAb (No. 35), which does
not react with granulocytes, gave tumour to normal
tissue ratios of 8 for intact McAb of 25 for F(ab')2
and 82 for Fab fragments (Buchegger et al. (1983)
J. Exp. Med., 158, 413). Since kidney elimination
was very fast for Fab, we selected F(ab')2 for
patients' studies. Thirteen patients with colon
carcinoma were injected with 1-123 (p,5n) (4-3mCi)
labelled F(ab')2 of MAb35 (1.5mg) and tested by
emission computerized tomography (ECT) with a
dual head rotating camera, 6, 24 and 48h after
injection. All 6 primary or recurrent tumours were
clearly detected by ECT as well as all 8 metastases
to the bone. Two small lung metastases were not
detected whereas 4 out of 8 liver metastases were
detected. Most of the tumours were already
detectable at 6h, but the best images were obtained
at 24h. Altogether 18 out of 24 tumour sites were
detected (Delaloye et al., Proc. Badgastein
Symposium, in press). In the positive cases the
tumour definition was markedly improved as
compared to previously reported results.
OPEN SESSION
(Chairman N.A. Wright)
Ultrastructural characterisation of leukaemic cells
with the immunogold method and monoclonal
antibodies
E. Matutes & D. Catovsky
MRC Leukaemia Unit, Royal Postgraduate Medical
School, London, W12 OHS, UK
Immunological characterisation of leukaemic cells
with cell lineage specific McAbs in conjunction with
cytochemical methods applied at electron
microscope level have increased the diagnostic
possibilities of otherwise unclassifiable leukaemias.
Ultrastructural and membrane marker analysis can
now be carried out simultaneously by using
different electron dense tracers. In this study, the
expression of specific membrane antigens in blast
cells from patients with acute leukaemias (AL) and
blast crisis (BC) from chronic granulocytic
leukaemias (CGL) is analysed by an
immunoelectron microscope method combined with
the myeloperoxidase (MPO), acid phosphatase (AP)
and platelet peroxidase (PPO) cytochemical
reactions. Reactive cells are identified under the
electron miscroscope by the immunogold technique
that uses a goat antimouse IgG coupled to 30nm
colloidal gold particles. The following McAbs have
been used: LICR-anti-glycophorin A- against
erythroid cells; AN51, C15-3, C17 and J15 against
platelet glycoproteins lb, Ila or Ilb/IlHa; BI-3C5
against lymphoblasts and early myeloid precursors;
My9 against myeloid precursors and J5 against
lymphoblasts. Our data show that this approach is
important for (1) the characterisation of the various
cell populations which proliferate in the 'mixed
leukaemias' (e.g. megakaryoblastic+lymphoid); and
(2) the identification of the different stages of cell
differentiation which can be found in particular
acute leukaemias, as defined by their reactivity with
distinct McAb and their enzyme activity (e.g. early552 ABSTRACTS OF ORAL PRESENTATIONS
acute myeloid leukaemias in which 3C5 + +, My9 -,
MPO - arefoundtogetherwith3C5+,My9 +, MPO+
blast cells).
New quantitative approaches in the investigation of
ABO-antigens and DNA-ploidy of human bladder
carcinoma
H. Feichtinger, H. Tanke, F. Hofstadter & G.
Jakse
University ofInnsbruck/University ofLeiden
Measurements of DNA-content and demonstration
of blood group antigens (BGA) on bladder
urothelial cells are often performed to obtain
prognostic information about the aggressiveness of
bladder tumours.
The aim of our study was first to develop a
cytochemical procedure for simultaneous staining of
DNA and BGA of urothelial cells in sections and
suspensions; secondly to overcome the problem of
subjective interpretation of BGA-staining by
measuring the immunoperoxidase staining product
quantitatively.
Briefly the method is based on Feulgen-Schiff
staining of DNA and subsequent
immunoperoxidase staining of BGA using
monoclonal antibodies.
A pilot study of 20 patients with bladder
tumours of various blood groups was performed.
DNA and BGA staining results were evaluated
quantitatively with a REICHERT scanning
cytofotometer. The data were compared with the
clinical course of the disease.
The quantitative evaluation and standardization
of differentiation antigens based upon histochemical
methods seems to be of major interest because of
their extreme heterogeneous expression in human
tumours.
Inmunocytology of CSF with a McAb panel
H.B. Coakham, B. Brownell, P.M. Allan, J.A.
Garson, E.I. Harper & J.T. Kempshead
Departments of Neurosurgery and Neuropathology,
Frenchay Hospital, Bristol, and ICRF Oncology
Laboratory, Institute of Child Health, London, UK
The considerable difficulties of routine CSF
cytology have been overcome by using McAb to
identify malignant cells. These include markers for
neuroectodermal tissue (UJi3A), epithelial
cytokeratin (LE61), leukocytes (2D1) and neoplastic
neuroblasts (UJ181-4). Additional antibodies were
used to refine diagnosis when appropriate. CSF
from patients with non-neoplastic conditions were
used as controls. In 17 cases of neoplastic
meningitis, 16 were correctly diagnosed and the
cells accurately categorised as carcinoma (5/6
cases), neuroectodermal tumour (8/8), and
lymphoma (3/3). Malignant cells were diagnosed in
94% of cases using immunocytology compared with
58% by routine cytology. The major advantage of
McAb analysis being the accurate categorisation of
malignant cell type. This has resulted in significant
changes in management in two particular instances;
where diagnosis was revised from carcinoma to
ependymoma and where unidentified malignant cells
were shown to be B-cell lymphoma.
McAbs to surface antigens of human neuroblastomas
K. Blaser, S. Sch6nmann, J. Iyer & H. Kaser
University ofBerne, Switzerland
Neuroblastomas are the most frequent solid
tumours in children. In contrast to other cancers,
spontaneous regression can be observed in some
cases, while only little progress in the therapy of
this tumour was made up to now. In order to
characterize the molecular structures displayed by
the surface of neuroblastoma cell membranes, we
produced McAbs which react with neuroblastoma
surface membranes. A number of McAbs against
the human neuroblastoma line IMR-32 was
obtained. The specificity of these antibodies was
tested by a radioimmunoassay (RIA) using cells of 4
different neuroblastoma lines, of several solid
tumours and various cells of different origin. Up to
now, we selected 5 McAbs which react only with
neuroblastomas and to some degree with melanoma
cells. In addition to RIA they were tested by
immunofluorescence staining. Furthermore,
neuroblastoma cells were internally labelled with
3 H galactosamine and membrane fragments,
obtained after stepwise centrifugation to 100,000 xg,
were treated with NP-40. Glycoproteins, recognized
by McAbs, were purified onto Sepharose-coupled
anti-mouse Ig and McAbs from ascites fluid.
According to SDS gel chromatography, the relevant
membrane compound is a glycoprotein of 18,000-
20,000d.ABSTRACTS OF ORAL PRESENTATIONS 553
Melanoma-associated antigens and nerve growth
factor receptor in human skin malignant melanoma
and benign nevocytic tumors.
A. Ranki, K.-M. Nieme, B. Atkinson, Z. Steplewski,
M. Herlyn & H. Koprowski
Department ofDermatology, Helsinki University and
Wistar Institute, Philadelphia, USA
Mouse monoclonal hybridoma antibodies against
human melanoma were used in an
immunoperoxidase assay on either frozen or fixed
samples of 50 primary and metastatic melanomas
and 40 benign nevi. Skin biopsies of PUVA-treated
psoriatics were examined, too. One antibody (IgGI)
immunoprecipitated a glycoprotein, another (IgGI)
a proteoglycan and a third (IgM) bound to most
melanoma cell lines in RIA. A fourth antibody
reacted with nerve growth factor receptor (NGFR).
Melanoma-associated antigens (MAA) defined by
one of the IgG antibodies were detected in all
primary and half of the metastatic melanomas but
also in a stratified pattern in the benign nevi.
Dysplastic nevi and Spitz tumors were positive but
halo nevi negative. This antibody retained its
activity in fixed tissue. The other IgG antibody
stained malignant melanocytes in only few primary
melanomas and the basal membrane zone in
psoriatic skin showing epidermal cell atypia. The
IgM antibody reacted with the malignant cells of
most primary and metastatic melanomas as well in
frozen as in fixed samples. Some intradermal
nevocytes in four benign nevi were stained, too. The
antibody detecting NGFR stained the epithelial
cells of the skin, some malignant melanoma cells
and some of the benign nevocyte tumours in a
stratified pattern. No correlation of the MAA
expression to Clark's classification was found. In
conclusion, melanomas show heterogeneity in the
expression of MAA and some benign nevocytes,
especially junctional ones and those in lower dermis
express MAA, possibly due to neural differentiation
or differences in melanogenesis.
Localisation of human placental alkaline phosphatase
in benign and malignant ovarian tumours
E.J. Nouwen, D.E. Pollet, J. Schelstraete, A. Van de
Voorde', C. Hansh & M.E. De Broe
Department of Nephrology, University Hospital of
Antwerp and 'Department of Molecular Biology,
State University ofGhent, Belgium
Human placental alkaline phosphatase (hPLAP)
was localised immunohistochemically on paraffin
F
sections of surgical biopsies from benign and
malignant ovarian tumours. An indirect avidin-
biotin-peroxidase staining procedure based on a
highly specific mouse McAb to hPLAP (E6) was
used. The pattern was compared to the
histochemical localisation of total alkaline
phosphatase on adjacent paraffin sections.
Quantitative estimation of the tissue hPLAP
content was performed by a specific enzyme-antigen
immunoassay based on the same monoclonal
antibody. Positive hPLAP staining was observed in
91% of the ovarian tumours investigated. A strong
correlation was present between the amount of
hPLAP in tissue extracts (from 3.0 to 557mUg-1)
and its immunohistochemical distribution. hPLAP
staining was localised in the tumour cells
predominantly at the level of the plasma membrane.
Strongest staining was present in 3 papillary
cystadeno-carcinomas. A case of mixed
heterologous Mullerian sarcoma was negative. The
low hPLAP level in a benign cystadenoma was still
8 times superior to the content of normal ovarian
tissue (1 mUg- ); hPLAP staining in the
cystadenoma was restricted to the tumoral
epithelium. Normal ovaries were devoid of hPLAP
staining, except for germinal inclusion cysts.
Oestrogen receptor expression association antigen in
breast and gynaecological carcinomas
K. Krohn, R. Ashorn, M. Helle' & P. Ashorn
Institute of Biomedical Science, University of
Tampere, and 'Mikkeli Central Hospital, Mikkeli,
Finland
McAbs to human milk fat globule (HMFG) detect
membrane antigens in breast and other carcinomas.
Of our 48 anti-HMFG McAbs, one detected
by immunodiffusion a secretory antigen both
in HMFG and in skimmed milk. Immuno-
histochemistry demonstrated the antigen in
the cytoplasm of breast carcinoma cells and
immunodiffusion in the ascites fluids of patients
with advanced intra-abdominal carcinoma
metastases. Gel filtration and radio immuno-
precipitation indicated that the mol. wt.
of the antigen was >400. SDS-PAGE revealed
at least 6 subunits with mol. wt. ranging from 44kd
to -200kd. Repetition of the antigenic epitope on
the subunits may be the basis of precipitability with
McAb. The presence of the antigen in breast and
gynaecological cancers correlated highly
significantly with the oestrogen receptor expression.
The antigen could thus be demonstrated in 10/12
oestrogen receptor positive but only 1/8 receptor
negative breast carcinomas. The use of the McAb in554 ABSTRACTS OF ORAL PRESENTATIONS
immunohistochemistry facilitates the assessment of
oestrogen receptor status of breast and
gynaecological cancers, including the extent of
heterogeneity within individual carcinomas.
Characterisation of McAbs to pancreatic cancer cell
structures
R. Arndt, W.H. Schmiegel, H. Kalthoff, J.
Gieseking, G. Skoppel, A. Ladak, V. Lampe & S.
Ulrich
Medical Clinic and Institute ofPathology, University
ofHamburg, W Germany
C 540H5 (IgG2bk), CtN3 (IgGiK) and Cl P83
(IgGlK) are McAbs generated by fusion of B-cells
from Balb/c mice immunised with human
pancreatic cancer cell lines (COLO 357, CAPAN 1).
Antibody C540H5 was bound to pancreatic cancer
cell lines (QGP-1, CAPAN-1, CAPAN-2, COLO
357, SW950), cholangio cancer cell line RPMI 7451
and bladder cancer cell line 647 V but only to 1/4
fibroblast cell lines in ELISA. Immunohistology
revealed strong reactivity of C 540H5 with 8/8
pancreatic tumours as well as with colon tumour,
gall bladder tumour and breast cancer whereas
there was a weaker reaction with 3/3 normal
pancreas and normal liver tissue.
Immunoprecipitation followed by SDS-PAGE and
autoradiography showed that the antigen
specifically bound by C540H5 is a protein with a
mol. wt. of 125kD. C1N3 was specifically bound to
4/5 pancreatic cancer but not to various fibroblast
and bladder cancer cell lines. Immunohistology
revealed strong reactivity of C1N3 with 10/12
pancreatic tumours and no reaction with 3/3
normal pancreas tissues. C1 P83 was specifically
bound to pancreatic cancer cell line QGP-1 and
cholangio cancer cell line RPMI 7451 and not to
various fibroblast and bladder cancer cell lines.
Immunohistology revealed strong reactivity of
C1 P83 with 6/6 pancreatic tumours but no
reactivity with 3/3 normal pancreas tissues as well
as with gall bladder, liver, colon, kidney and spleen.
Clinical significance of in vitro maturation defect of
monocytes in cancer patients
Z. Rudolf, G. Sera & G. Krosl
The Institute ofOncology, Ljubljana, Yugoslavia
Defect of in vitro maturation of monocytes has
been assayed in 70 cancer patients and in healthy
donors. The mean value of mature cells as well as
the mean value of maturation index (MI) was
significantly lower in cancer patients when
compared with control group (P=0.001). The mean
value of MI was in 52 patients with malignant
melanoma 8 +6%, in patients with colorectal
carcinoma 11+8%, while in healthy donors it was
44+ 14%. A correlation could be established
between MI and the extent of disease. Patients in
stage I displayed the mean value of 7.1%, in stage
III (regional metastatic disease) the mean value was
5.2%, while in patients with disseminated disease
(stage IV) the mean value was 3%. The maturation
defect was associated with yet unknown serum
factor, and the mean value of MI in autologous
sera was decreased (8+6% vs. 6+5%). In a smaller
group of patients the MI was being tested at
different phases of the disease and the findings
correlated with the response to treatment. A
marked increase in MI values was noted in patients
with complete response, while in patients with
progressive disease the observed values of MI were
markedly decreased.
Criteria for the selection of McAbs suited for
immunoscintigraphy
K. Bosslet, G. Luben, H. Harthus, U. Rausch', J.
Mollenhauerl, H. Kern' & H.H. Sedlacek
Research Laboratories of Behringwerke AG, and
'Institute for Cell Biology, University of Marburg,
FRG
McAbs induced by immunisation with the PaTull
pancreatic adenocarcinoma cell lines were screened
for specifiy using histology combined with the
immunoperoxidase method on cryopreserved
human pancreatic carcinoma, pancreatitis and
normal pancreatic tissue. Five McAbs of the
following specificity were evaluated for their
capacity to localise in pancreatic carcinomas
xenografted to nude mice.
The localisation indices of the 1311-labelled
McAbs were determined according to Br. J. Cancer,
(1981), 44, 91. Despite the fact that the antigens
recognised by the different McAbs are expressed at
similar quantities (2-5 x 105 antigen molecules/cell)
on the plasma membrane of in vitro cultured
pancreatic carcinoma cell lines, the localisation
indices varied from 1 (for 227/19, no localisation)
up to 7 (250/183). In this respect, the affinity of the
McAbs and antigen shedding are important
contributory factors.ABSTRACTS OF ORAL PRESENTATIONS 555
Pancreatic Normalpancreatic Reactivity with MW ofantigens
McAb carcinoma tissue nude mouse tissue detected
227/18 + + + + 130kD
227/19 + + +macrophages 43kD
406/14 + + (+)/+ducts 200kD
431/13 + + 180kD
250/183 + + 180OkD
Radiolabelied McAbs for tumour immunodetection:
Comparison between two indium chelating agents
J.Y. Douillard, J.C. Saccavini, J.F. Chatal & B.P.
Le Mevel
INSERM U 211, UER Medecine, Nantes, France
Indium-labelled McAbs with tumour specificity
have already been utilised to localise tumours by
immunoscanning. Non-specific accumulation in the
liver was consistently noticed and considered as a
major problem for liver metastasis detection.
In order to reduce the non-specific binding of In-
111 McAb to normal tissues, two chelating agents,
DTPA or TTHA, were comparatively used to bind
In-111 to gastrointestinal tumour-specific McAb.
Biodistribution was analysed by sacrificing nude
mice bearing human colon carcinoma at different
time points after injection of In- 11 -labelled specific
McAb. Results obtained at all the times of the
experiments (1, 5 and 7 days) show quite similar
antibody distribution independently of the chelating
agent used for In-Ill labelling. Non-specific
accumulation occurred mainly in liver, spleen,
kidney, skin and bone, with a slight advantage to
DTPA over TTHA resulting in higher
tumour/normal tissue ratios. Tumour/liver,
T/spleen, T/kidney, T/skin and T/bone ratios were
below 1, reflecting the non-specific binding of In-
111 McAb to normal tissues, for both DTPA and
TTHA In-Il l-labelled antibodies. Non-specific
binding of In-111-labelled McAb to normal tissues
does not favour the use of In-11 as a radionuclide
for tumour detection with radiolabelled McAb in
cancer patients.
Improved tumour localisation using subtraction of
indium-labelled specific and gallium-labelled non-
specific antibody
H. Haisma, W. Goedemans & J. Hilkens
Antoni van Leeuwenhoekhuis, Plesmanlaan 121,
Amsterdam, The Netherlands
A murine McAb, reactive with human mammary
tumours, was radiolabelled with In-l 11 and injected
into nude mice bearing human tumour xenografts,
together with Ga-67 radiolabelled non-specific Ig.
Tumours could be visualised clearly with the In-
labelled specific antibody, but an improved
localisation was obtained when the image was
subtracted with the image of the Ga-labelled non-
specific antibody. Tumour to tissue contrast was
improved from 2.9 to 7.6 after subtraction.
In- 111 radiolabelled antibodies showed higher
tumour to tissue ratios than 1-123 radiolabelled
antibodies. It was shown that two biochemically
related isotopes, In- 111 and Ga-67, could be
imaged at the same time using a gamma camera in
dual isotope mode. Overlap of each isotope in the
other isotope channel was <20%. Indium and
gallium-labelled antibodies could be injected
simultaneously and images could be produced up to
5 days after injection.
This technique offers advantages over previously
used subtraction methods which use Tc-99m
albumin and pertechnetate for subtraction of blood
pool activity of the radiolabelled antibody. The
antibody used for subtraction is injected
simultaneously with the specific antibody and does
not have to be injected before each scan.
Furthermore, the use of a second antibody seems
more appropriate, as the distribution of this
antibody in non-malignant tissue is identical to the
distribution of the specific antibody.
WAYS TO IMPROVE LOCALISATION
(Chairman J.P. Lavender)
Radioimaging of melanoma lesions with McAbs to a
human high molecular weight melanoma associated
antigen
S. Ferrone, P. Giacomini, L. Callegaro, U. Rosa &
G. Buraggi
Department of Microbiology and Immunology, New
York Medical College, Valhalla, NY, USA
The high mol. wt. melanoma associated antigen
(HMW-MAA) has the following properties: (i) it is
expressed by at least 90% of melanoma lesions, is556 ABSTRACTS OF ORAL PRESENTATIONS
not detectable in normal tissues except for hair
bulbs and is found in minute amounts in serum; (ii)
it has a density of - 2 x106 antigenic sites/cell on
the melanoma cell line Colo 38; (iii) it is not
susceptible to antibody mediated modulation, even if
the incubation is made in the presence of antimouse
Ig xenoantibodies; (iv) anti HMW-MAA McAbs
149.63, 225.28S and 763.74T have high affinity since
their association binding constants were found to be
1.01 x 108moles xl-1, 0.98 x 108moles x l- l and
1.26 x 108moles x 1-1, respectively. Injection of
131I-McAb 225.28S into patients with melanoma
could visualise malignant lesions within 60min, but
was also associated with accumulation of
radioactivity in liver, spleen and bone marrow. This
background is likely to be caused by the uptake of
the antibody (complexed with the circulating
HMW-MAA?) by Fc receptor bearing cells, since it
was markedly reduced when Fab2 fragments were
injected into patients. Fab2 fragments of the McAb
225.28S labelled with 1251 1311j "'In and 99mTc
were effective in visualising malignant lesions in 11
of the 18 patients investigated. Lesions with a
diameter of at least 2.5cm could be detected. These
results suggest that the HMW-MAA is a useful
marker for radioimaging, provided that Fab2
fragments are utilised.
The use of second antibody to improve selective
localisation of tumours: Animal model studies
K.A. Chester, R.H.J. Begent, B. Pedley, P.A. Keep,
J.A. Boden, F. Searle & K.D. Bagshawe
Department of Medical Oncology, Charing Cross
Hospital, London, W6 8RF, UK
The potential of tumour directed (antitumour)
antibodies for localisation and therapy of cancer is
limited by the relatively large proportion of
administered antibody which remains in the normal
tissue. Second antibody, directed against the
antitumour antibody, may be used as a tool to
facilitate clearance of non-tumour associated
antitumour antibody.
The effect of second antibody on tumour and
normal tissue localisation of 125I-labelled goat
antibody directed against carcinoembryonic antigen
(antiCEA) was investigated in nude mice bearing
human colorectal carcinoma xenografts. Second
antibody clearance of 125I-labelled mouse
monoclonal antibody directed against human
chorionic gonadotrophin was studied in rabbits.
Results showed that second antibody,
administered 6h after antiCEA at 10 times the dose,
was able to cause a 10-fold reduction in circulating
antiCEA and an 8-fold increase in tumour: blood
ratios in mice. In rabbits a 40-fold reduction of
control values for circulating monoclonal antibody
was achieved and there were no clinical or
histological indications of immune complex-
mediated illness.
These results indicate that second antibody could
be used to improve tumour discrimination for
location and therapy of cancer.
The use of second antibody to improve selective
localisation of tumours: Clinical studies
R.H.J. Begent, A.J. Green, K.A. Chester, P.A.
Keep, F. Searle & K.D. Bagshawe
Department of Medical Oncology, Charing Cross
Hospital, London, W6 8RF, UK.
Localisation of cancer by external scintigraphy after
i.v. injection of radiolabelled anti-tumour (first)
antibody is hampered by the high proportion of
antibody which persists in normal tissues. We have
previously shown in animals that non-tumour-
bound first antibody could be cleared from normal
tissues by second antibody directed against the anti-
tumour antibody. The second antibody could either
be free or entrapped in liposomes. Eight patients
have received liposome entrapped second antibody
(LESA): in 5, goat antiCEA was the first antibody,
and in 3, mouse monoclonal antibody (17-lA) was
used. Second antibodies were horse and rabbit
respectively. Good clearance of first antibody was
seen in all those with adequate doses of LESA.
Tumour images were enhanced in this way.
Fourteen patients have received free second
antibody (rabbit anti-mouse). Clearance of first
antibody was achieved for 5 patients receiving 17-
IA antibody and 5 with mouse monoclonal
antibody to HCG. Tumour images were thus
enhanced. Two McAbs (antiCEA and antiAFP)
failed to clear with free second antibody. When
favourable combinations of first and second
antibody are used either LESA or free second
antibody can enhance tumour imaging and may
have application in improving the therapeutic ratio
of antibody directed therapy of cancer.
Experience with '23I-labelled McAbs
K.E. Britton & M. Granowska
Department of Nuclear Medicine, St Bartholomew's
Hospital, London, ECJ, UK
Tumour associated McAbs, may be labelled with
1231 using the mild iodogen technique which byABSTRACTS OF ORAL PRESENTATIONS 557
direct immunoassay causes no reduction in
immunoreactivity. Since the majority of uptake of
labelled McAbs in vivo is completed by 24h, the use
of short-lived 1231 (13.2h half life, y energy
0.159 MeV, no beta radiation) is feasible. The
maximum uptake of the injected McAb is of the
order of 7%, usually 1-2%, thus initially the blood
and tissue background is high. Two approaches to
imaging may be compared: early imaging with 1231
for high count rate and good statistical data,
coupled with a technique for background correction
by subtracting an early blood pool image from the
later blood pool and uptake images using a
repositioning protocol for the patients and their
computer images together with a temporal change
detection algorithm; or late imaging with a long-
lived radionuclide such as 1311 with improved target
to noise ratios but at the expense of poor sensitivity
and poor statistics. Over 10 times the count rate is
obtained using 1231 over 1311 for the same
administered dose and for a lesser radiation dose.
In one child with neuroblastoma imaged with 1311
UJ13A, the tumour was evident only after 5 days,
whereas in the same child imaged with 1231 UJ13A,
the tumour was well visualised at 24h even without
computer analysis. 1231 labelled HMFG2 McAb has
been used successfully to image known ovarian
cancer and its spread, with a 90% correlation with
the surgical findings in a prospective study. McAbs
labelled with 1231 are excellent for the early imaging
of the distribution and response to chemotherapy of
malignant disease, for counts count in nuclear
medicine.
111-Indium-labelled antibodies for tumour detection
D.S. Fairweather, A.R. Bradwell, N. Baggett, S.
Chandler' & P.W. Dykes
Departments of Immunology and Chemistry,
University of Birmingham, and 1Department of
Nuclear Medicine, Queen Elizabeth Hospital,
Birmingham, UK
Tumour detection using radiolabelled antibodies
has been shown to be a sensitive and specific
technique. 131Iodine is frequently used as the
radiolabel but produces high energy gamma and
beta emissions which are disadvantageous.
1l'ndium, by contrast, has a much more suitable
gamma ray and is known to be a stable cell label.
We have labelled antibodies to carcinoembryonic
antigen (CEA) with "1'In and used them for
tumour detection in comparison with 13'Iodine
labelled antiCEA, (131-I-aCEA). DTPA was
covalently coupled to sheep antiCEA using a mixed
anhydride. 74MBq of 111In chloride was
neutralised with 0.3 M acetate (pH6.5), mixed with
0.8mg of modified antibody, and left at 4°C
overnight. Unbound 1"'in was removed by gel-
filtration. Labelling efficiency was 50-75% giving a
specific activity of up to 74MBq/mg protein. Eleven
patients with CEA producing tumours were studied;
5 had repeat scans using the same dose of 131-I-
aCEA. 131I did not accumulate in any organ and
was rapidly excreted in the urine. With Indium,
20% of the injected dose accumulated in the liver,
10% was excreted in the first 24h and 3%//day
thereafter. Whole body absorbed radiation doses
were similar for both isotopes but count rates with
"'In were 3-fold higher. The 11 patients had 31
potential tumour areas. Twenty-eight were positive
by the "'in scans and 25 positive by a
combination of conventional clinical tests. The 5
patients scanned with both isotopes had 15
potential tumour areas. 13 were detected with "'1in
and 8 with 131. The "1'In scans also achieved
higher statistical significance. Despite similar
dosimetry, "1In is clearly a superior isotope to '31I
for scanning. This is due to higher count rates and
prolonged tumour residence of Indium giving
improved picture contrast.
Improved radiolocalisation using other than
intravenous routes of antibody administration
A.A. Epenetos
On behalf of Hammersmith Oncology Group, Royal
Postgraduate Medical School, Hammersmith
Hospital, London, and the Imperial Cancer Research
Fund, London, UK
Using a paired antibody technique (including
specific and non-specific radio-iodinated antibodies)
we showed that although good tumour to non-
tumour (T:NT) ratios could be obtained in patients
with various epithelial neoplasms, the absolute
amount of specific radiolabelled antibody targeted
to tumours was small (-0.01% of injected amount
g 1 tumour 1 day post-administration).
Thus, we investigated other routes of antibody
administration. We found improved T:NT and
significantly higher absolute antibody uptake when
radiolabelled antibodies were given i.p. to patients
with ovarian cancer, intralymphatically to patients
with lymph node metastases secondary to cervical
cancer, intrapleurally to patients with intractable
pleural effusion, intrapericardially to patients with
pericardial effusion and impending cardiac
tamponade, and as an intra-arterial infusion in
patients with gliomas.
These routes of antibody administration offer the
advantages of diminished catabolism and558 ABSTRACTS OF ORAL PRESENTATIONS
dehalogenation of radio-iodinated antibodies and
high antibody concentration for longer periods of
time in the vicinity of tumours. In this way,
radiolabelled antibodies can be used successfully for
the diagnosis and possible therapy of some forms of
malignant disease.
OTHER POTENTIAL DIAGNOSTIC USES
OF ANTIBODIES
(Chairman A.J. Munro)
Gadolinium-DTPA as a contrast agent in magnetic
resonance imaging
D.H. Carr', J. Brown2, G.M. Bydderl, I.R. Young3
& R.E. Steiner'
'Department of Diagnostic Radiology and
2Department of Clinical Pharmacology, Royal
Postgraduate Medical School, Hammersmith
Hospital, London, and 3Picker International,
Wembley, Middlesex, UK
Forty-six patients were examined on a 0.15 Tesla
superconducting imaging system before and after
intravenous administration of Gd-DTPA (Schering)
in a dose of 0.1mmolkg- . The 46 patients
included 20 with malignant cerebral tumours, 5
with non-malignant disease of the brain, 12 with
tumours of the liver (benign and malignant), 5 with
renal tumours, as well as patients with tumours in
the bladder, pancreas, femur and mediastinum. All
20 patients with cerebral tumours showed
enhancement. In 14/20 cases, contrast enhancement
allowed the differentiation between tumoral and
peritumoral oedema to be made. Enhancement was
noted in all the other patients with the effects being
most marked on inversion recovery scans. No
significant abnormality was noted in any
haematological or biochemical parameter after Gd-
DPTA administration. Intravenous Gadolinium-
DPTA promises to be a useful adjunct in magnetic
resonance imaging.
The measurement of regional tissue function using
positron emission tomography
R.P. Beaney, D.J. Brooks, K.E. Halnan & T. Jones
MRC Cyclotron Unit, Hammersmith Hospital,
London, W12 OHS, UK
With the advent of positron emission tomography it
has become possible to measure the regional tissue
concentration of a positron emitting radionuclide in
absolute units (Bqml-'). Using the sequentially
inhaled tracers C'502 and "CO it is possible to
measure regional blood flow and blood volume in
man non-invasively. The uptake of any blood-borne
tracer is governed not only by regional tissue
perfusion (supply), but also by the regional
extraction by the tissue. Consequently by measuring
both the regional tissue uptake of a tracer and
regional blood flow one can derive the regional
extraction of the tracer by means of positron
emission tomography. It is relatively easy to correct
for the blood pool by using the regional blood
volume data obtained after the inhalation of "CO.
To date most tumour PET studies have dealt
with the tissue extraction of molecular '502, the
glucose analogue '8F-2-deoxyglucose and the cation
82-Rubidium. The same technique, however, has
been used to measure the extraction of 11C-
Albumin and "C-labelled BCNU in brain tumours
and can easily be extended to measure the tissue
uptake ofsuitably labelled McAbs.
Anti-CEA gamma camera scintigraphy with different
antibodies and radionuclides
P.O. Schnell, S. Hammarstr6m, S. von
Krusenstierna, S.A. Larsson, G. Lundell & B.
Wahren
Karolinska Hospital, Stockholm, Sweden
Our earlier studies with goat antibodies labelled
with 13"I or 123I resulted in detection of 50-60% of
known gastrointestinal tumours.
In some of the examinations we have used
SPECT with a rotating gamma camera in
combination with conventional gamma camera
scintigraphy.
In an attempt to improve the results we have
used, in the last year, monkey anti-CEA and
monoclonal mouse anti-CEA (McAb 38S1). The
results are seen in the following table:
No. oftumours % detected
Monkey (macaca irus)
anti-CEA- 3II 30 80
Mouse
McAb 38S1-131I 30 73
The change of antibodies has improved the
detectability of human CEA-producing tumours in
our studies to 70-80%. A new method developed by
Dr E. Sundrehagen, Radiumhospitalet, Oslo,
Norway, to label IgG with 99Tcm has been tested in
vitro. Preliminary results have given a labelling
yield of -85%.ABSTRACTS OF ORAL PRESENTATIONS 559
Immunoscintigraphy with 99mTc labelled F(ab')2
fragments of a melanoma associated McAb
G. Paganelli & P. Riva
Department of Nuclear Medicine, Ospedale Generale
Provinciale "M. Bufalini", Cesena, Italy
Twelve patients with stage III or IV malignant
melanoma were studied wvith 99mTc labelled F(ab')2
fragments of a melanoma associated McAb
(Tecnemab-1, Sorin-Biomedica, Italy). The amount
of administered antibody ranged from 100 to 200,ug
of protein labelled with 8mCi (296 MBq) 99mTc. No
adverse reactions were observed.
Conventional clinical investigation revealed 68
metastatic sites. Of these, 49 (72%) were detected by
immunoscintigraphy. Immunoscintigraphy also
showed 31 further positive scans, 11 of which were
confirmed by further investigations. Patients were
scanned at 4, 8 and 24h after i.v. injection, the best
images being obtained at 8 and 24h.
This work is part of a multicentre clinical trial
"Immunoscintigraphy of malignant melanoma"
conducted by the National Research Council,
Special Project on Biomedical and Clinical
Engineering.
Clinical use of radiolabelled tumour-associated
antibodies: State of the art and future prospects
N. Pateisky, K. Philipp & J. Burchell
Department of Obstetrics and Gynaecology,
University of Vienna, and ICRF, London, UK
The aim of this study was to examine the clinical
value of radioimmuno-localisation in patients with
carcinoma of the ovary, cervix uteri and breast
using the tumour-associated McAb HMFG2.
Fifteen patients were studied and the results from
antibody scans were compared to surgical findings.
123I labelled antibody was given to patients either
i.v. or s.c. Both routes of administration were found
to be of clinical value. The i.v. route was useful in
establishing the diagnosis and in the follow-up of
patients, whilst the s.c. route was useful in the pre-
operative assessment of lymph node status. The
number of patients studied so far is small but the
accuracy of this test appears to be high.
In 1969 Gitsch and co-workers introduced intra-
operative lymphoscintigraphy in an attempt to
improve the accuracy of lymph node dissection in
patients with cervical cancer. It is possible that the
accuracy of lymphoscintigraphy could be improved
by using radiolabelled McAbs such as HMFG2.
THERAPEUTIC APPLICATIONS OF
ANTIBODIES IN VITRO
(Chairman D.A.G. Galton)
Antibody-ricin conjugates: A method of conjugation
that blocks the galactose recognition site on the B-
chain
B. Foxwell, P. Thorpe & W. Ross'
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, WC2A 3PX, and 1Institute of Cancer
Research, Fulham Road, London, SW3, UK
Ricin, the toxic lectin from castor bean, is a
glycoprotein which consists of two polypeptide
chains, A and B, linked by a disulphide bond. Ricin
exerts its toxic action by binding to cell surface
oligosaccharide structures via a galactose
recognition site on the B-chain. This is followed by
the internalization of at least the A-chain which
subsequently catalytically inactivates 60S ribosomal
subunits.
Recently, attempts have been made to target ricin
to malignant cells by covalently linking it to McAbs
directed against neoplastic tissues. Two approaches
of antibody-ricin conjugate construction have so far
been used. One method is to link the isolated A-
chain by a disulphide bond to the antibody. Some
conjugates of this type have proved capable of
highly specific toxicity to cells bearing the
appropriate antigen. Unfortunately many of these
A-chain conjugates are poor cytotoxins probably
because, lacking the B-chain, they are unable to
penetrate cells as efficiently as native ricin.
A second approach is to link the intact toxin to
the antibody; a method has been developed that
produces a blockade of the galactose binding site
on the B-chain and so prevents non-specific toxicity.
Such conjugates have been found in tissue culture
test systems to have a 104-fold greater toxicity
towards cells bearing the target antigen than to
those without it. The conjugates are also highly
effective at killing cells in murine tumour models.
They were able to kill 99.99% of i.p. administered
tumour cells when injected 24h later i.p. I.v.
injection reduced effectiveness by 10-fold.
Use of McAbs for removal of unwanted cells from
harvested bone marrow (BM)
J.M. Goldman
MRC Leukaemia Unit, Royal Postgraduate Medical
School, London, UK
Immunological techniques involving the use of
McAbs can be used in vitro either to remove560 ABSTRACTS OF ORAL PRESENTATIONS
neoplastic cells from harvested BM before
autografting or to deplete allogeneic BM of T-
lymphocytes in the hope of suppressing or
preventing graft-versus-host disease (GVHD). One
may rely either on the opsonizing capacity of a
non-complement-fixing IgGMcAb or on the direct
complement-dependent cytotoxicity in vitro of an
IgM McAb.
Autografting after purging marrow: The use of
McAbs to purge BM in acute leukaemia depends
on the assumption, which may not be valid, that
normal and leukaemic stem cells are antigenically
distinguishable. The J5McAb (directed against
common-ALL antigen) has been used to treat
autologous BM before autografting for patients
with ALL in second remission. The development of
myeloid McAb should permit this technique to be
applied in AML.
T-cell depletion before allogeneic BM
transplantation: The Royal Free Hospital team has
recently reported the use of two anti-T cell McAbs
in combination followed by treatment with rabbit
complement to remove T-lymphocytes from donor
BM. This technique appears to reduce very
substantially the incidence and severity of GVHD.
At the Hammersmith we have used a human
complement-fixing IgM McAb designated Campath-
1 to treat BM in vitro. The speed of engraftment of
BM from HLA-identical sibling donors resembles
that of untreated BM and the severity of GVHD
seems to be reduced; engraftment of mis-matched
BM cells may however be compromised by such T-
cell depletion.
Ways to improve the in vitro cytotoxicity of
immunotoxins
A. Frankel, D. Ring, L. Greenfield & M. Bjorn
Cetus Corporation, Emeryville, California, USA
Seventy McAbs to human breast cancer-associated
antigens were linked by SPDP to ricin toxin A
chain and tested on three breast cancer cell lines
and one normal fibroblast cell line for their ability
to inhibit protein synthesis. Factors that predicted
in vitro potency were IgG class, cell surface binding,
high affinity and high antigen copy number per cell.
Several of the McAbs were linked by 2-
iminothiolane or MBS to ricin A chain. Only
disulfide linkages to ricin A chain yielded active
immunotoxins.
Several of the McAbs were linked by SPDP or
MBS to diphtheria A chain, CRM45, MSP
(Greenfield, L., 1983, Proc. Natl Assoc. Sci., 80,
5683) and MSP-SA (spacer arm) and tested for
cytotoxicity. Only the genetically engineered MSP-
SA containing the diphtheria hydrophobic region
and a spacer arm was active in vitro. Another toxin
moiety, PAPII, was conjugated via SPDP or 2-
iminothiolane to McAbs and yielded conjugates less
active than ricin A chain.
T-cell depletion of human bone marrow using T101
A-chain immunotoxin
G. Laurent, P. Poncelet, A. Fauser1, J.M. Derocq
& F.K. Jansen
Centre de Recherche Clin-Midy-SANOFI,
Montpellier, France, and 1Medizinische Universitat
Klinik, Freiburg, FRG
Acute graft versus host disease (GVHD) has, for
years, been the major cause of morbidity during the
initial one to two months following allogeneic bone
marrow transplantation (BMT). Many experiments
in animals, as well as a number of human trials,
have shown that it could be greatly reduced if
mature T lymphocytes were removed from the
donor marrow. In an attempt to abrogate acute
GVHD, anti-T cell immunotoxins (IT) offer an
efficient option. An anti-human T-cell A-chain-IT
was prepared by coupling ricin A-chain with the
McAb TIOI, and evaluated for both efficacy and
tolerance.
Under defined conditions, T101-A-IT allowed: (1)
a reduction of the PHA, con A and mixed
lymphocyte culture to levels below background; (2)
a cyto-reduction of more than 2 logs of the mature
T lymphocytes evaluated in a clonogenic assay.
With regard to tolerance, no toxicity of stem cells
could be found using CFU-GM, BFU-E and CFU-
GEMM assays up to the concentration of 10-8M.
These results show that the use of T101-A-IT is a
simple, reliable, highly efficient and safe approach
to the in vitro treatment of bone marrow in
allogeneic transplantation.
Activity and specificity of abrin and ricin
immunotoxins
0. Fodstad, A. Godal & A. PihI
Norsk Hydro's Institutefor Cancer Research and the
Norwegian Cancer Society, Oslo, Norway
Conjugates of abrin and ricin with antibodies
directed against human melanoma-associated
antigens (250K and p210) were prepared. The
conjugates were tested against a panel of melanoma
cell lines with different degrees of expression of the
antigens.ABSTRACTS OF ORAL PRESENTATIONS 561
The abrin conjugates exhibited greater toxicity
and specificity than the corresponding ricin
conjugates. The toxicity, as measured by the
inhibition of cellular protein synthesis, was related
to both the degree of expression of the appropriate
antigen and to the different sensitivities of the cells
to the unconjugated toxin. Addition of free
antibody strongly reduced the toxicity of the
conjugates to antigen positive cells, but had no
effect on non-melanoma control cells.
THERAPEUTIC APPLICATIONS OF
ANTIBODIES IN VIVO
(Chairman A.A. Epenetos)
The cellular expression of a heavy chain linked
idiotypic determinant recognised by a monoclonal
anti-idiotypic antibody in a lymphoma patient and his
relatives
J.A. Habeshaw, L.C. Walker & S Dhut
ICRF Department of Medical Oncology, St
Bartholomew's Hospital, London, UK
McAbs reactive with idiotypic determinants of a
paraprotein JSIgGlA were characterised by their
reactivity with Fab, and isolated H chain and L
chain determinants. Three McAbs were reactive
with a conformational determinant requiring both
heavy and light chain association, 6 identified heavy
chain determinants, and 7 reacted with A chain. A
McAb 2H3.D8 reactive with heavy chain idiotype
was used to detect expression of this idiotype by
tumour cells from the patient J.S., and by B
lymphocytes in the blood of his mother, his two
brothers, and his daughter. The idiotype detected
by 2H3.D8 was expressed on 0.15% of maternal B
cells and was found in lower or similar frequency in
normal controls. In the patient 72% of circulating B
cells expressed this determinant. In both brothers,
and in the daughter, 2H3.D8 idiotype was expressed
on 10% (±2%) of circulating B cells. Similar values
for expression of this idiotype were obtained from
studies of the serum Ig in the patient's family. These
results suggest the occurrence of heavy chain linked
2H3.D8 idiotype is a genetically determined
dominant characteristic inherited through the
patient's father. Cross reactivity of McAb 2H3.D8
was not observed in panel testing of over 70 other
paraproteins.
Radiolabelled antibodies: Dosimetry studies
M.J. Myers & G.R. Hooker
Department of Medical Physics, Hammersmith
Hospital, London, UK
I.v. injection of radiolabelled antibodies has been
shown, by post-operative sampling, to yield too low
an absolute uptake of activity by the tumour for
therapeutic applications. Therapy has been directed
instead to the treatment of tumours of peritoneal,
pleural and pericardiac cavities where the
radiolabelled antibody can be administered into an
enclosed space and tumour uptake relative to
normal or whole body uptake improved to practical
levels. In order to calculate the radiation dose
received by the tumour and by normal tissues it is
necessary to know the activity and its residence
time in a particular volume of tissue. The
therapeutic study is therefore divided into two
phases. The first employs a relatively small amount
of activity (usually 1mCi of 1311) attached to the
antibody. Sequential quantitative whole body
imaging using a scintillation camera/computer
system gives the time course and distribution of the
administered activity. Other imaging modalities
such as X-ray CT and ultrasound aid the
estimation of the volume of distribution in the
tumour (this is the least accurately measured
parameter and may lead to gross errors in the final
dosimetric calculations). Based on these findings
and on the dose estimated to be received by normal
organs and the whole body a therapeutic dose (of
the order of 20-50mCi) can be administered as
phase two of the study in the same way as in phase
one. The localisation and time course of the
therapeutic activity can be monitored only
approximately to confirm the previous estimated
radiation dose. The results of six studies using 1311
labelled HMFG1 and HMFG2 tumour-associated
antibodies are outlined and the method of dose
calculation detailed.
McAb targeting anti-cancer drugs
R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, UK
Tumour localizing McAbs have considerable
potential for targeting chemotherapeutic agents
since they provide a means for the selective delivery
of drugs to a local tumour, or more particularly, to
metastases. There are several inter-related steps in
designing drug-antibody conjugates for therapy.
This includes selection of McAbs which localize in
tumours ideally with little or no uptake into normal
tissues. Also for effective delivery of drugs linked to
antibody, conjugates should uniformly penetrate
regions of the tumour which are contributing to its
progressive growth. The amount of antibody which
can be deposited in a tumour must also be562 ABSTRACTS OF ORAL PRESENTATIONS
sufficient to provide targeting of appropriate levels
of drug.
There are several factors to be taken into account
in designing drug-antibody conjugates depending
upon the final stage involved in drug transfer to
tumour cell. One approach is to covalently link
antibody to drug so that after antibody binding to
the tumour cell it will internalize as an intact
conjugate so allowing the drug moiety to exert its
cytotoxic effect. Antibodies may also be used to
target drugs to tumour so that after localization the
drug moiety may be released and function as free
drug.
These concepts and development will be
illustrated by considering the tumour localizing
properties of McAb 791T/36. The construction and
evaluation of 791T/36 antibody conjugate will be
considered with respect to chemotherapeutic agents
including methotrexate, daunomycin, vindesine and
interferon as an immunomodulating agent.
cages are bound per dextran. These conjugates have
been demonstrated to be biologically active vs IgM,
with affinity chromatography (sepharose-bound
IgM). Preliminary studies with the U698 cell line
(which has IgM on the cell membrane) have shown
that following a 30min incubation period with the
boronated McAbs described above, significant
binding to the U698 cells was achieved. Direct
boron assay indciated - 5 ug boron g-' cells.
Collaborative studies are underway with Dr
Soldano Ferrone, to prepare similar McAbs
directed to human melanoma.
Research supported by NIH Grant No. CA32920
and the U.S.D.O.E.
McAbs of therapeutic potential which interact with
host effector systems
Boron-l1-labelled antibodies for neutron capture
therapy
R.G. Fairchild, J.J. Elmore, D.C. Borg, P. Micca,
D. Gabel & B.H. Laster
Medical Department, Brookhaven National
Laboratory, Upton, New York, USA
If they were truly tumour specific, McAbs would
provide unique access to various tumours. In fact,
therapeutic application of radiolabelled antibodies
delivers significant doses to normal cell pools which
compete for the McAbs. This problem can be
circumvented by targeting stable (non-toxic)
isotopes to tumour via McAbs, which can
subsequently be activated by external radiation
beams. Competing normal cell pools can then be
excluded from the treatment volume. Such a
technique is available via the 10B(n,cx)7Li reaction.
Calculations show that therapeutic amounts of 10B
can be delivered assuming 103 10B atoms per McAb,
and 106 antigen sites per cell (-15,ug 10B per g
tumour). Direct conjugation of such amounts of B
to McAbs is difficult. We are using dextrans as
"bridges" to enhance the carrying capacity of
McAbs. Experiments to date indicate that -1,000
boron atoms can be attached to McAbs via dextran
bridges while still retaining biological activity. Three
to five dextrans (40k dalton) have been successfully
attached to anti-IgM antibodies. These are
subsequently reacted with amine derivatives of
decachlorocarboranes, so that an average of -20
M. Clark, S. Cobbold, G. Hale & H. Waldmann
Department of Pathology, University of Cambridge,
UK
Rat McAbs made against various subpopulations
of mouse and human haemopoietic cells have been
tested for their ability to eliminate these cells both
in vitro and in vivo using host effector systems.
Many rat IgM and IgG antibodies against human
cells are effective at promoting human complement
mediated lysis and an example of such an antibody
CAMPATH1 (Hale et al., 1983, Blood, 62, 873),
with specificity for human lymphocytes is presently
being tested clinically for its ability to prevent
GvHD in bone marrow transplantation.
Complement mediated lysis with IgG antibodies of
less potency can be improved by preparing the
monovalent antibody (Cobbold & Waldmann,
1984, Nature, in press).
In tests of antibody dependent cell-mediated
cytotoxicity using human lymphocytes as effectors
no killing was observed with 18 IgM, 23 IgG2a or
4 IgG2c antibodies but all 21 IgG2b antibodies
tested gave killing even at high dilution (Hale et al.,
1984, Biochem. Soc. Trans., in press).
Various isotypes of rat antibodies against mouse
lymphocyte subpopulations were tested for their
ability to suppress in vivo immune responses and
graft rejection. Only antibodies of the IgG2b
isotype were found to work (Cobbold et al., 1983,
Mol. Biol. Med., 1, 285). It seems clear from these
results that antibody isotype as well as specificity
will determine the therapeutic potential of McAbs.ABSTRACTS OF ORAL PRESENTATIONS 563
Therapeutic use of monoclonal anti-idiotype
antibodies against B-cell lymphoma
E.M. Rankin, A. Hekman, R. Somers & W.W. ten
Bokkel Huinink
The Netherlands Cancer Institute, Plesmanlaan 121,
Amsterdam, The Netherlands
Two monoclonal anti-idiotype antibodies have been
used for the treatment of advanced centrocytic
lymphoma, antibody T2 for patient Top, and
antibody KI for patient Kos. Both antibodies were
of the IgG2a subclass, were cytotoxic with rabbit
but not with human complement, and did not
modulate the antigen in vitro. Patient Top had
10 x 109 malignant lymphocytes in the blood, and a
negligible amount of free idiotype. A variety of
different schedules of administration, daily dosage
doubling, hourly dosage doubling and continuous
low-dose infusion were tried, all resulted in a
temporary fall in the level of lymphocytes. At the
end of the continuous infusions, free antibody was
detectable in the serum, and cells in blood, bone
marrow, lymph node and ascites were coated with
antibody. 1lIndium oxine labelled lymphocytes
were cleared from the circulation which was rapidly
populated with unlabelled cells. The S-phase cells in
the blood and 3H-thymidine uptake did not alter
during treatment. Lytic cells, a sign of necrosis,
increased in the lymph nodes from 0 to 25%.
Monocyte activity improved during treatment.
Patient Kos had large amounts of free idiotype in
the circulation. This was removed by antibody Ki,
and coating of cells with KI in blood, lymph node
and ascites was demonstrated, excess K1 was
detectable in the serum at 20 ugml-'.
Both patients have had a minimal response to
treatment. 3.8 g T2, and 5.9g KI were given
without any toxicity. No modulation of the antigen,
and no antibodies to the mouse Ig were seen.
Treatment of chronic lymphatic leukaemia with
monoclonal anti-idiotypic antibodies
P.J.A. Capel, F.W.M.B. Preijers & W. Allebes
Department of Nephrology, Radboud Hospital,
Nijmegen, The Netherlands
A McAb of the IgGl subclass reactive with the
idiotype of the leukaemic B-cells of a BCLL patient
was raised. This antibody did not show any cross
reactivity with other cells or tissues, and in total 40
grams of anti-idiotypic antibody was purified from
ascites. Because human Fc receptors are
polymorphic (only 70% of normal individuals can
react with murine IgGI), the patient's Fc receptors
were typed and showed to be reactive with murine
IgGl. The patient had a high level of free
circulating idiotype (150ygml-1) and upon in vivo
treatment the free idiotype was cleared without any
signs of serum sickness or other side effects. After
the removal of free idiotype a strong tumour
reduction was observed. The swollen lymph nodes
decreased to a normal size and the spleen, with a
weight of - 4kg, reduced 20% in size. In vivo a
moderate modulation of the antigen was present
but the idiotype was re-expressed within 16h.
During repeating treatments the in vivo modulation
became more pronounced and the therapy lost its
effectiveness. Due to antigen modulation
immunotoxins might be effective in such case.
Therefore ricin A chain was conjugated to the anti-
idiotype and tested in vitro for specific cell killing.
The specific toxicity of the immunotoxins was too
low to consider any therapeutical use. This low
specific toxicity was most likely due to a low
idiotype expression of the B-CLL cells.
We may conclude that murine IgGI anti-
idiotypic antibodies are effective in vivo without any
side effects even in the presence of high levels of
free idiotype, but due to antigen modulation this
type of therapy was only partially effective.
Cell-mediated lysis of glioma cells directed by
McAbs
Th. Bilzer, D. Stavroul & W. Mellert1
Lehrstuhl far Allg. Pathol. und Neuropathol., &
'Abt. Funktionelle Pathol., Institut far
Tierpathologie, University ofMunich, W Germany
A McAb (14AC 1) has been used for directing T
cell-mediated antibody-dependent cytotoxicity
(ADCC) against the syngeneic glioma cell line
79FR-G-41, derived from a N-methyl-N-
nitrosourea induced rat astrocytoma. Hybridomas
were established by fusion of the non-producing
X63-AG8.653 mouse myeloma line and spleen cells
from BALB/c mice immunized with 79FR-G-41
cells (Stavrou et al. (1983) Eur. J. Cancer Clin.
Oncol., 19, 1439). Products of the 14AC 1 clone
show specific binding avidity and are characterized
as belonging to the IgG2 isotype.
T cells have been enriched from thymus or
peripheral blood of normal syngeneic Fischer rats
(F344). Effector cells were non-adherent, non-
phagocytic and surface-Ig negative. For ADCC
glioma cells as well as syngeneic brain cells were
triggered with serum-free hybridoma supernatants.
In comparison with natural T cell-mediated
cytotoxicity effector cells revealed a 50% increase564 ABSTRACTS OF ORAL PRESENTATIONS
of reactivity against antibody-coated glioma cells,
whereas no cytotoxicity could be induced by
coating the brain cells.
A model for cell killing using radiolabelled antibodies
A.T.M. Vaughan, A.R. Bradwell, J. Taylor & P.W.
Dykes
Department of Immunology, University of
Birmingham, UK
A nine parameter model for the killing of tumour
cells using radiolabelled antibodies has been
developed. Included are physical variables such as
isotope half-life and decay mode plus kinetic
information of antibody uptake and tumour
retention.
From the results it is self-evident that a high
tumour uptake contributes to increased tumour
dose. Less obvious is the dosimetric consequences
of the interplay between isotope half-life, antibody
uptake and subsequent loss from the tumour. A
long-lived isotope gives a low body dose when en
route to the target and allows more time for
clearance from normal tissues while tumour
irradiation is proceeding. Both these effects act to
increase tumour specificity and depend upon a
prolonged tumour residence time for the isotope.
Currently the isotope which appears most suitable
as a toxic radiolabel is the 64h half-life beta
emitter, 90-Yttrium, incorporated in a chelate link
(as with 111-Indium) onto the antibody.
Boron slow neutron capture with colloidal cobalt
boride conjugated to McAb
C.H. Poynton, R.S. Tilbury, J. Head, S.E. Tindle,
K.A. Dicke, L.J. Peters & C.L. Reading
University of Texas MD Anderson Hospital and
Tumor Institute, Houston, Texas, USA.
In the course of preparing colloidal
immunomagnetic fluids for cell separation in bone
marrow transplantation we have found it possible
to incorporate a large amount of boron into the
colloidal particles in the form of cobalt boride.
Cobalt chloride can be reduced by sodium
borohydride to form colloidal cobalt boride
particles of an even size (electron microscopy),
which can be varied from 22-55 nm in diameter.
The colloid is made in a human albumin solution
which is then cross linked around the particles with
glutaraldehyde followed by borohydride reduction.
A McAb is then coupled to the albumin with
benzoquinone. Emission spectroscopy of the
lyophilized immunocolloid in 10% serum shows a
B:Co ratio of 1:11 by weight. We have used the
McAb CF-I on the boride colloid, which reacts
with close to 100% of K562 erythroleukaemic cells
(grown in boron-free cell culture medium). The cells
are thoroughly washed after the incubation with the
colloid. By this method a boron content of
120nMoles was obtained per 107 cells lyophilized,
giving a theoretical number of 1.4 x 109° 'B atoms
per cell. We are in the process of measuring the
boron content of cells incubated with non-reactive
colloid and are now attempting to determine the
flux of slow neutrons required to kill only colloid
coated K562 cells: Viability is measured in a
leukaemic cell colony assay since K562 cells have a
high plating efficiency. Thermal neutron beams are
generated at the TRIGA nuclear reactor at Texas A
& M University with fluxes up to
1.7x 109ncm2sec-1. We have also measured 24Na
production since the cells are suspended in PBS.
We are investigating the toxicity of the procedure
to normal haemopoietic progenitors with
clonogenic assays. Further neutron irradiations are
in progress.
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Identification of bladder carcinoma cells by McAbs
R. Arndt, H. Huland, H. Durkop, F. Donn & T.
Loning
Department of Immunology, Medical Clinic,
Departments of Urology and Pathology, University
ofHamburg, W Germany
In order to establish McAbs for immunotherapy of
bladder cancer we generated a series of hybridomas
by fusion of B-cells from Balb/c mice immunized
with human bladder carcinoma cell lines (Mano,
486P). Here we present the data of two McAbs.
Antibody Mano 4/4 (isotype IgGI) reacts with a
28kd cell surface protein of bladder cancer cells.
Immunohistology revealed a strong reactivity of
Mano 4/4 in 18/19 bladder cancer. The antigen,
designated UP28, is predominantly expressed on
those tumour cells which show invasive growth.
UP28 is expressed in low concentration on a
subpopulation of normal bladder cells which is
located in the basal layer of the epithelium.
Antibody 486 P-3-12-1 reacts strongly with a cell
surface antigen which is found on 17/19 bladder
tumours so far tested. This antigen is expressed on
single bladder epithelial cells which are located in
foci in the intermediate and/or superficial layer ofABSTRACTS OF ORAL PRESENTATIONS 565
the normal bladder epithelium. The expression of
the antigen on these cells is of particular interest,
because of the focal appearance of bladder cancer.
Higher density on the cell surface and expression
on the vast majority of bladder cancers independent
of grading and staging favours Mano 4/4 and 486
P-3-12-1 as candidates for immunotherapeutical
application.
Expression of the T67 antigen on B cell malignant
disorders. Correlation with other immunological
markers
G. Laurent, E. Kuhlein', J.F. Brunet' & G. Delsol2
Centre de Recherche Clin-Midy-SANOFI,
Montpellier, 'Laboratoire d'Immunologie, Toulouse,
2CHU Purpan, Toulouse, France.
Several McAbs (TlOl, leu 1, 10-2) have been
described to detect 67,000-71,000 antigen (Tp67
molecule) present on normal and malignant T
lymphocytes. The presence of this antigen on
neoplastic B cells is also well established.
Nevertheless, little attention has been given to the
relationship with other cell markers. Using
immunofluorescence, 56 cases of B-CLL cells were
investigated: the mean percentage value of Tp67
+B-CLL was 82.7%±15%. The mean value of
Tp67+OKT3- cells was 73%±18%, thus well
correlated with the mean of surface Ig (SIg)+ cells
(77%±19%). No correlation between the percentage
of Tp67+ cells and serum Ig levels, monoclonal
protein spike, SmIg phenotype, or clinical staging
was found, whereas a slight correlation with mouse
rosette forming cells was observed.
Using immunoperoxidase technique on frozen
sections, 69 cases of B cell lymphoma were studied:
Tp67 antigen was found in 24 cases, mostly in low
grade lymphomas. In follicular lymphomas. two
results deserve attention: (1) TIOI + lymphomas
most frequently showed IgM +IgD+Slg. Inversely,
T101 unreactive lymphomas displayed IgM+IgD-
phenotype. (2) Tp67 antigen and CALLA (Gp 100)
were found to be mutually exclusive. These findings
are important in the context of B cell differentiation
pathways.
Human placental alkaline phosphatase (hPLAP) as a
tumour marker in serum and tissue extracts
D.E. Pollett, E.J. Nouwen, J. Schelstraete, A. Van
de Voordel, P. Blockx2 & M.E. De Broe
Department of Nephrology and 2Department of
Nuclear Medicine, University of Antwerp, and
'Department of Molecular Biology, State University
ofGhent, Belgium
An enzyme antigen immunoassay based on a highly
specific McAb against hPLAP was used to quantify
hPLAP in: serum of blood donors, serum of
unselected hospital patients, serum of cancer
patients, butanol extracts of normal tissue, and
butanol extracts of surgical tumour biopsies.
Carcinoembryonic antigen (CEA) was determined
by RIA when increased levels of hPLAP were
found.
The normal reference limit (P98 value) in serum
of healthy blood donors (n=117) was 0.051IU -,
in serum of unselected hospital patients (n= 1650) it
was 0.1IU -'. In tissue extracts the P98 value was
0.8mUg-' tissue (lung tissue excluded). Normal
lung tissue had a higher hPLAP content than all
other normal tissues examined.
We found that 9.8% of all cancer patients, and
40% of ovarian cancer patients had increased
hPLAP serum levels. Increased hPLAP in serum
(>O.1IU1 ') was accompanied by increased CEA
(>Sngml-') in 50% of all cases analysed (n=20).
Serum hPLAP levels of >0.2IU1-1 were always an
indication for an important tumour load. Increased
hPLAP was found in 49% of all tumour biopsies
and in 90% of ovarian neoplasia biopsies.
First and second antibodies
radioimmunodetection of tumours
for the
A.R. Bradwell, D.S. Fairweather, A. Keeling, P.
Hawker, A. Vaughan & P.W. Dykes
Department of Immunology, Medical School,
Birmingham University, UK
The major limiting factor in the detection of
tumours using radiolabelled antibodies is the ratio
of the antibody bound to the tumour compared
with that in the surrounding normal tissues.
Attempts to increase this ratio have centered on the
use of affinity purified antibodies, McAbs and
antibody fragments. An alternative approach is to
reduce the non-bound antibody counts, particularly
those present in the circulation. This has been
achieved using a second antibody, both in a rat
model and in humans. In the rat model 10 animals
were given '3tlodine labelled sheep anti-CEA (A)
and 24h later pig anti-sheep IgG (B) or pig IgG
(controls). After a further 24h the circulating
counts in the test rats had fallen to one-seventh of
those in the controls. To understand the mechanism
we incubated human macrophages with Igs from 5
different animals. Those Igs that bound to the Fc
receptors (using a rosette test) on the macrophages,566 ABSTRACTS OF ORAL PRESENTATIONS
i.e. rabbit, pig and mouse, were considered useful
second antibodies because immune complexes
containing them would be rapidly catabolised. In
contrast, antibodies with no uptake on human Fc
receptors (sheep and, goat) are useful primary
antibodies because they do not falsely accumulate
in macrophage containing tissues. We subsequently
studied 3 patients with tumours. Two were given A
and then a day later B (in a 15-fold molar excess).
Over the next few hours the circulating counts fell 3
times faster than in patients not given second
antibodies (the spleen accumulated the
radioactivity) but tumour counts were maintained.
The third patient was given a mouse McAb IgM
anti-CEA first antibody and a sheep anti-mouse
IgM second antibody. No increased clearance of
circulating radioactivity occurred. Thus the use of a
"clearing" second antibody led to improvements in
tumour uptake ratios and to improved tumour
detection.
A comparison of radiolabelled McAbs and their
F(ab')2 fragments in direct radioimmunoassays and in
xenografted nude mice
H. Durbin, S.J. Mather, R.H. Raymond, E. Cliff &
W.F. Bodmer
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, WC2A 3PX, UK
F(ab')2 fragments oftwo McAbs H17E2 and AUA-1
were prepared by pepsin digestion of the Ig and
purified by affinity and size exclusion
chromatography. Direct binding radioassays were
performed on purified antigen preparations or
relevant tumour cell lines either in solid phase or as
live cell suspensions. Biodistribution experiments
were performed in nude mice bearing colorectal
tumour xenografts using radiolabelled Ig and
F(ab')2 preparations. Clearance rates, tumour
uptake and tumour (T) to blood (B) and tumour to
organ (0) ratios for the two antibody species were
calcujated. In general T:B and T:O ratios for
F(ab')2 were significantly higher than for intact
antibody. F(ab')2 clearance rates were faster while
absolute tumour uptakes were similar.
These results suggest that, for diagnostic
immunoscintigraphy, radiolabelled F(ab')2
preparations are likely to be preferable to intact Igs.
Antigen detection by McAbs following
electromagnetic field exposures of human colon
cancer cells
W.D. Winters, M.P. Moyer & J.L. Phillips
University of Texas Health Science Center and
Cancer Therapy and Research Center, San Antonio,
Texas 78284, USA
Present information suggests that a major target
site for electromagnetic (EM) field effects may be
the cell membrane. We have used a set of McAbs
produced to human colon cancer antigens as
specific probes for changes in cells exposed to EM
fields. Human colon cancer cells were exposed
concurrently to EM fields (E+M+), magnetic fields
alone (M+), electric fields alone (E+) and to no
fields (E-M) using a specially designed,
standardized EM exposure facility (E+
=300mA/M2 RMS; M+=1.0 or 0.5gauss RMS).
Equal numbers of cells of each tumour type were
exposed to the EM fields for 0, 6, 12 and 24h at
37°C, resuspended in fresh medium and cultured for
3 days in 5% CO2 at 37°C. Equal numbers of cells
from each exposure group were reacted first with
McAbs then with 125I-labelled anti-mouse IgG
serum with appropriate wash cycles between.
Radioactivity in final cell pellets was counted in a
gamma counter.
Results showed that the level of antigens detected
by McAbs markedly increased in colon cancer cells
at the time of exposure to E+M+ and M+ at 1.0
gauss increased, as compared to E-M - controls.
These data showed that time dependent exposures
to M+ and E+M+ fields induced marked changes
in the levels of specific human colon cancer cell
surface antigens.
Supported in part by New York State
Department of Health Power Lines Project HRI-
21082-07.
Parameters influencing the uptake of radiolabelled
McAb 96.5 in heterotransplanted malignant
melanoma in nude rats
K. Ydstrom, S.-E. Strand, C. Ingvar, P.-E.
J6nsson, T. Brodin, H.-D. Sjogren & K. Wingardh
Departments of Surgery, Radiation Physics and the
Wallenberg Laboratory, University ofLund, Sweden
In this study McAb 96.5, specific for melanoma
antigen p97, was labelled with 1251 by three different
techniques: Lactoperoxidase (LPO), Cloramine-T
(CLT) and Bolton-Hunter (BH). As a control the
antibody 1.4 (labelled with 13l1) or human serum
albumin was used for evaluation of non-specific
uptake. The blood pool was evaluated in the
tumour with in vivo 9QTcm-labelled red blood cells.
Blood flow measurements were performed with a
microspheres technique.ABSTRACTS OF ORAL PRESENTATIONS 567
Nude athymic rats, weighing 150-300g (n=70),
transplanted with human melanoma were used as
animal model. Scintillation camera measurements
and blood samples were taken during 1 to 5 days.
The rats were then sacrificed and tissue samples
were measured for radioactivity. The specific
activity uptake in the tumour for the McAb 96.5
was dependent on tumour wt. For tumours
weighing <0.3g the specific uptake was 2-3 times
higher than for larger tumours. The biological half-
life in the whole body was -80-125h for antibody
96.5 and 30-50h for control antibody 1.4.
Tumour/organ ratios were calculated and in the
order of 0.3-0.6 for T/blood, 1.9-2.0 for T/liver and
3.3-4.6 for T/muscle.
This study was supported with grants from the
Swedish Medical Research Council, Swedish Cancer
Society and Ake Wibergs Foundation.
Elimination of malignant cells from bone marrow in
autologous rescue (ABMT)
R. Buckman, R.C. Coombes, A.J. Forester, V.
Shepherd, R.A.J. Mcllhinney & A.M. Neville
Ludwig Institute of Cancer Research and Institute of
Cancer Research, Royal Marsden Hospital, Sutton,
Surrey, UK
High dose chemotherapy is feasible when used with
autologous bone marrow (BM) rescue. Malignant
cells, however, that may be present in BM provide
a potential source of future metastases.
Immunological methods are being used as a BM
"clean up" procedure.
We used an antibody (FIB-75) which recognises
an antigen present on almost all epithelial tissues
but not on BM stem cells. We demonstrated
(Lancet, (1982) ii, 1428) that, in conjunction with
exogenous rabbit complement (RC), this antibody
can eliminate malignant cells in BM up to an
infiltration of 1% with acceptable toxicity to CFU-
C.
For large scale trials RC is technically awkward
to use and thus we conjugated FIB to the A chains
of ricin and abrin toxins. FIB-ricin at 10-7M and
FIB-abrin at 10-8M showed abolition of protein
synthesis and clonogenicity of all cell lines tested.
There was acceptable toxicity to CFU-C (mean
62%, range 25-93%, N=22) and mixed stem cell
cultures (GEMM).
Targeting of radiolabelled or toxin conjugated
McAbs to human tumours
S. Canevari, S. Menard, S. Miotti, R. Orlandi, M.
Ripamonti & M.I. Colnaghi
Istituto Nazionale Tumori, Milan, Italy
McAbs were raised against human ovary or breast
cancer in the perspective of diagnostic and
therapeutic clinical applications. After a complete
study of their specificities we focused on two
McAbs of IgM class, MRrl and MOv2, respectively
recognizing an antigen of epithelial cells of normal
and cancerous mammary gland and an antigen
present on epithelial ovarian carcinomas. In vivo
distribution and half-life of McAbs in various
conditions of injection and radiolabelling were
studied in nude mice with transplanted mammary
or ovarian tumour.
McAbs intravenously injected showed a very
rapid elimination from the blood and no
preferential uptake in subcutaneously growing
tumours; McAbs intraperitoneally injected, in spite
of a quite short half-life, localized in tumour
nodules grown in the peritoneal cavity of pristane
primed nude mice. The same McAbs have been
developed as carriers of cytotoxic agents. Linkage of
McAbs to ricin A chain has produced conjugates
that display in vitro specific cytotoxicity for tumour
cell lines with relevant target antigens. To plan a
more efficient therapeutical administration of
immunotoxins, kinetics of cytotoxicity have to be
compared with in vivo McAbs' half-life.
Induction of surface changes, membrane traffic
alteration and growth delay on rat glioma cells by a
McAb
T. Lederer, D. Stavroul, W. Mellert' & K.S.
Zanker
Institute of Experimental Surgery, Technical
University, and 'Department of Functional
Pathology, University ofMunich, W Germany
In the investigation presented here, we examined
the cell surface changes, the membrane traffic of 75-
Se-methionine and growth delay of cultured rat
glioma cells (79FR-G-41) in the presence of the
McAb 14AC1. The production and characterization
of the antibody used was described recently
(Stavrou et al. (1983 Eur. J. Cancer Clin. Oncol., 19,
1439). Incubation of 5 x 10' cells with appropriate
dilutions of the monoclonal antibody caused
noticeable cell surface alterations. A major568 ABSTRACTS OF ORAL PRESENTATIONS
proportion of the Falcon flask attached cells, mostly
growing flat, floated as spheres and lacked the
commonly seen surface differentiations as microvilli
and membrane ruffling; holes within the membrane
were not observed by SCANS. Pre-incubation of
the native cells with the antibody resulted in a
diminished 75-Se-methionine uptake and the release
of the label into the medium was dose-dependent
reduced, when the antibody was allowed to react
with cell surface structures. Only a small amount of
the floating cells was dead. The remaining cells
could be replated and attached to the flask, but did
not continue to differentiate into their common
morphological feature or to grow. These
experiments suggest that the McAb alters cell sur-
face structures, complement-independent, in such a
way that detachment and growth delay occurs,
likely due to arrested/suppressed membrane traffic
of precursor molecules. Particular blocking during
the cell cycle and/or shifting into G0-phase is under
current investigation.
Cervical cancer: Differences in expression of
cytokeratin polypeptides associated with malignant
change
C. A. Makin1, L.G. Bobrow1 2 & W.F. Bodmer1
1Imperial Cancer Research Fund, London,
2Department of Histopathology, University College
Hospital, London, UK
Antisera and McAbs recognising intermediate
filaments are acknowledged to be of use in surgical
pathology. Most workers, however, have utilised
freshly frozen tissue sections or special fixatives. The
McAb CAM5.2, which identifies the lower mol. wt.
cytokeratin polypeptides found in secretory
epithelia, has been shown to react consistently on
formalin fixed paraffin embedded tissue sections.
Preliminary studies using the immunoperoxidase
technique indicated that CAM5.2 positively stained
the endocervical glands of the normal cervix, as
opposed to the ectocervix, which was negative: all
invasive carcinomas of the cervix stained positively.
The change in expression of cytokeratin
polypeptides with the development of malignancy in
the cervix has been assessed in varying degrees of
intraepithelial neoplasia and invasive carcinoma.
Uniformly positive staining was noted in all
invasive carcinomas, whereas the 10 cases of
intraepithelial neoplasia studied were generally
negative with some areas of equivocal staining. Our
results suggest that as the extocervic becomes more
dysplastic the cells start to manufacture the lower
mol. wt., more embryonic forms of cytokeratin
polypeptides. By the time the invasive stage is
reached all cells are positive with CAM5.2 implying
that the cells in the more malignant tumour have
not differentiated in terms of their cytokeratin
expression. CAM5.2 can be used clinically to
distinguish normal ectocervical epithelium from
invasive carcinoma and is of use in assessing the
development ofintra-epithelial neoplasia.
Application of a McAb (H317) to detection of
placental type alkaline phosphatase (PLAP) in
ovarian cancer
P.J. McLaughlin, M. Critchley, P.M. Tromans &
P.M. Johnson
Departments of Immunology, Nuclear Medicine and
Obstetrics and Gynaecology, University ofLiverpool,
UK
Placental-type alkaline phosphatases comprise a
polymorphic group of enzymes in which two major
forms can be distinguished: the "placental" and
"placental-like" alkaline phosphatases (PLAP and
placental-like AP, respectively). Both forms of the
enzyme have been described as tumour products,
and these correspond to the so-called Regan
(PLAP) and Nagao (placental-like AP) enzymes.
We have studied in depth a McAb H317 reactive
with PLAP but not with placental-like AP or any
non-placental tissue alkaline phosphatase
isoenzymes. This McAb has formed the basis of a
solid-phase enzyme immunoassay detecting
>0.1UI1 PLAP (McLaughlin (1983) et al., Clin
Chim. Acta, 130, 199). In this assay 26/65 (40%) of
ovarian cancer sera had detectable PLAP whereas
PLAP was not found in any control sera. It
appears that the circulating form of enzyme in
healthy individuals is the placental-like AP and is
thus unreactive with H317 (McLaughlin et al.
(1984) J. Clin. Pathol., in press). Thus, H317 may
detect a more specific tumour marker within this
enzyme group. The H317 McAb is also being used in
in vivo antibody-guided radioimaging of ovarian
cancer patients. The aim of this study is to evaluate
123I-labelled H317 McAb as a radioimaging agent
for epithelial ovarian tumours 1-4 years after
removal of the primary. The patient is injected i.v.
with 74MBq (2mCi) 123I-H317 (2mg mouse IgG).
Using a large field of view gamma camera, anterior
and posterior images are made at 10min, 4h and
24h. In a preliminary study on 9 patients, three
patterns of distribution were seen, viz. (i) focal
accumulation of the 123I-H317 in areas of
secondary involvement, (ii) diffuse uptake in
abdomen and pelvis, and (iii) "cold" areas. Surgical
confirmation of recurrence was possible in some
cases.ABSTRACTS OF ORAL PRESENTATIONS 569
Heterogeneity in small cell lung carcinomas
F.M. Moss, L.G. Bobrow, M. Sheppard, D. Rowe,
R.L. Souhami & P.C.L. Beverley
ICRE Human Tumour Immunology Group,
University College, London, UK
Small cell carcinomas of the lung are a group of
bronchial tumours distinct from non-small cell
carcinomas both in their clinical behaviour and
therapeutic response. Usually regarded as a single
class there is, nevertheless, histological, clinical and
therapeutic heterogeneity within the group. A panel
of McAbs has been used to stain a series of small
cell carcinomas. This has revealed heterogeneity
both within and between tumours. Characterisation
of antigenic heterogeneity may provide an
additional method of classification of tumours
within this group.